Nanyang Biologics enters business combination with RF Acquisition Corp II for $1.5B listing.

Nanyang Biologics Pte. Ltd., a pioneer in AI drug discovery, has entered into a business combination agreement with RF Acquisition Corp II for a US$1.5B transaction. The Company offers a comprehensive drug discovery platform and has a patented flagship product, NB-A002, a first-in-class DNA Damage Response therapeutic candidate targeting ILF2. Their patented Drug-Target Interaction Graph Neural Network (DTIGN) model enables faster identification of potential drugs. The transaction aims to pursue a public listing.